Vascular Endothelial Growth Factor (e.g., Vegf-a, Vegf-b, Etc.) Or Derivative Patents (Class 514/8.1)
-
Patent number: 11866739Abstract: The present invention is directed to ligand binding molecules and uses thereof to modulate angiogenesis and/or lymphangiogenesis.Type: GrantFiled: October 4, 2019Date of Patent: January 9, 2024Assignee: VEGENICS PTY LIMITEDInventors: Michael Gerometta, Timothy Adams
-
Patent number: 11786556Abstract: The present invention relates to a method for preparing a growth-factors containing platelet releasate from a fluid mammalian platelet concentrate, comprising the consecutive steps of subjecting the platelet concentrate to a pathogen reduction step to disrupt non-enveloped viruses; subjecting the platelet concentrate to an activation step to cause the platelets to release growth factors; recovering a fibrinogen depleted fluid platelet releasate; subjecting the fibrinogen depleted fluid platelet releasate to a second pathogen concentration reduction step to disrupt enveloped viruses; subjecting the platelet releasate to sterile filtering and recovering a filtrate liquid containing the growth factors. The platelet releasate obtained with the method of the present invention may be used as a therapeutic agent to enhance the proliferation of multi lineage cells in regenerative medicine and in the management of non healing wounds and resistant ulcers.Type: GrantFiled: November 20, 2017Date of Patent: October 17, 2023Assignee: Power of Platelets Pte. Ltd.Inventors: Theo Gooris, Hossam Mostafa Fahmy
-
Patent number: 11752468Abstract: Provided herein are materials and methods for the preparation of blood products. In one aspect, provided herein is a composition including platelets or platelet derivatives and an aqueous medium, wherein the aqueous medium has a protein concentration less than 50% of the protein concentration of donor apheresis plasma.Type: GrantFiled: November 16, 2022Date of Patent: September 12, 2023Assignee: Cellphire, Inc.Inventors: Joshua Donald Montgomery, Braden Carl Ishler, Stephen Edward Amos, Keith Andrew Moskowitz, Amber Nicole Lee, Rafael Jorda, Glen Michael Fitzpatrick, Michael Alexander Mathews
-
Patent number: 11712452Abstract: The present disclosure relates to methods for treating or preventing heart failure in subjects with elevated left ventricular end systolic volume (LVESV). In particular, the present disclosure relates to methods for treating or preventing heart failure in subjects with a LVESV of greater than 70 ml (>70 ml).Type: GrantFiled: December 22, 2015Date of Patent: August 1, 2023Assignee: MESOBLAST INTERNATIONAL SÀRLInventors: Silviu Itescu, Lee Golden
-
Patent number: 11679075Abstract: There is disclosed a method for administration of a formulation of resiniferatoxin (RTX) to provide cardiac sympathetic afferent denervation when applied in an amount and concentration sufficient to chemically denervate vanilloid 1 receptor (TRPV1)-expressing CSAR (cardiac sympathetic afferent reflex) afferents. There is further disclosed a method for treating heart failure or hypertension and its related indications selected from the group consisting of increased sympatho-excitation, cardiac hypertrophy, increased left ventricular end diastolic pressure (LVEDP), lung edema, and combinations thereof, comprising administering an effective amount of RTX directly to a tissue site selected from the group consisting of epicardium, a T1-T4 dorsal root ganglion and intrathecally to the T1-T4 region of the spinal column.Type: GrantFiled: June 24, 2020Date of Patent: June 20, 2023Assignee: Board of Regents of the University of NebraskaInventors: Irving H. Zucker, Hanjun Wang
-
Patent number: 11633432Abstract: A human amniotic fluid formulation has been developed for topical application to the eye, which is useful for the treatment of ocular diseases and injuries including dry eyes, Sjogren's Syndrome, cataracts, burns and injuries to the eye tissues. The formulation is a sterile de-cellularized human amniotic fluid (D-HAF), devoid of amniotic stem cells and elements of micronized membrane or chorion particles. Methods for treating, or preventing various ocular diseases, injuries and disorders using the formulation, optionally in combination with one or more therapeutic, prophylactic or diagnostic agents are described.Type: GrantFiled: June 29, 2018Date of Patent: April 25, 2023Assignee: MAM HOLDINGS OF WEST FLORIDA, L.L.C.Inventor: Carl Randall Harrell
-
Patent number: 11597909Abstract: The invention relates to a method for the formation of renal tubules by embedding individual renal cells into a synthetic hydrogel, which is based on polyethylene glycol as a component, and the culturing of the cells until tubule structures are formed. The culturing can be continued until the obtained tubule structures correspond in terms of size, structure, morphology and functionality to adult human renal tubules or are at least similar thereto.Type: GrantFiled: May 12, 2017Date of Patent: March 7, 2023Assignee: LEIBNIZ-INSTITUT FÜR POLYMER-FORSCHUNG DRESDEN E.V.Inventors: Heather Weber, Mikhail Tsurkan, Valentina Magno, Uwe Freudenberg, Carsten Werner
-
Patent number: 11564694Abstract: A smart tourniquet for self-administering a medication is provided. When a patient needs to inject themselves with a medication, intravenously, called an “infusion,” the patient wears the smart tourniquet around their arm and tightens the device. While the patient is using the smart tourniquet, the device automatically records the date and time of the infusion, called a “timestamp”. The patient can also use the device to record the dosage or “number of units” taken at the time of the infusion. The smart tourniquet can store the timestamp as well as other related information as a record. At a later time, the patient can recall prior records on the smart tourniquet itself. The smart tourniquet can also be synchronized with an application and the records can be downloaded for review by the patient, nurse or doctor to render accurate and timely care.Type: GrantFiled: January 11, 2018Date of Patent: January 31, 2023Assignee: TAKEDA PHARMACEUTICAL COMPANY LIMITEDInventors: Danielle Bateman, Qi-Dong Dai, Qing Gu, Seok-Choon Toh
-
Patent number: 11529084Abstract: The detection and diagnosis of a variety of cardiovascular disorders and levels of heart condition, using a novel method and system, according to a comprehensive analysis of cardiac electrical signal via the frequency domain, time domain, spatial domain.Type: GrantFiled: September 8, 2015Date of Patent: December 20, 2022Inventor: Dan Qun Fang
-
Patent number: 11464727Abstract: The present invention discloses a number of formulations (including some that comprise Lunasin and reduce the visible signs of ageing by reducing skin wrinkles) that can be used as body-wash and related skin and hair treatments that can be manufactured using high quality ingredients at a reasonable cost, lower than comparable available products.Type: GrantFiled: September 29, 2020Date of Patent: October 11, 2022Assignee: SERENDIPITY TECHNOLOGIES LLCInventor: Amen Dhyllon
-
Patent number: 11459565Abstract: Embodiments of the disclosure include methods and compositions for the renewal of cardiomyocytes by targeting the Hippo pathway. In particular embodiments, an individual with a need for cardiomyocyte renewal is provided an effective amount of a shRNA molecule that targets the Sav1 gene. Particular shRNA sequences are disclosed.Type: GrantFiled: November 12, 2020Date of Patent: October 4, 2022Assignee: BAYLOR COLLEGE OF MEDICINEInventors: James F. Martin, Yuka Morikawa, Todd Ryan Heallen, John Leach
-
Patent number: 11453708Abstract: New designed ankyrin repeat proteins with binding specificity for HGF are described, as well as nucleic acids encoding such HGF binding proteins, pharmaceutical compositions comprising such proteins and the use of such proteins in the treatment of diseases.Type: GrantFiled: June 2, 2014Date of Patent: September 27, 2022Assignee: MOLECULAR PARTNERS AGInventors: Gaby Tresch, Talitha Bakker, Douglas Phillips, Frieder W. Merz, Kaspar H. Binz
-
Patent number: 11406676Abstract: The present disclosure provides viral microparticles comprising genetically-engineered baculoviruses (at least partially) embedded in a polymeric matrix for the local delivery of therapeutic nucleic acid molecules to the cells of a vertebrate individual (optionally in combination with a medical implant such as vascular stent platform). The viral microparticles are especially useful for promoting the healing of a wound as well as the repair of a blood vessel and prevent pathological scarring. Also provided herein are processes for making the viral microparticles, pharmaceutical compositions comprising viral microparticles as well as supports comprising the viral microparticles for the locating the viral microparticles in a wound or in the vicinity of a wound.Type: GrantFiled: August 20, 2018Date of Patent: August 9, 2022Assignee: MANGOGEN PHARMA INC.Inventors: Satya Prakash, Arghya Paul, Dominique Shum-Tim
-
Patent number: 11400142Abstract: The present invention relates to the use of plasminogen in the prevention and/or treatment of diabetic neuropathic pain and neurohypersensitivity, and in the repair of nerve tissue injury. Therefore, plasminogen may become a new strategy for preventing and treating diabetic neuropathic pain.Type: GrantFiled: December 16, 2016Date of Patent: August 2, 2022Assignee: Talengen International LimitedInventor: Jinan Li
-
Patent number: 11369596Abstract: The present invention provides a method of treating or ameliorating a neurodegenerative disease in a mammal, the method comprising administering to the mammal a therapeutically effective amount of a neurodegenerative disease drug, wherein the drug is a substrate of an ABC transporter inhibitor, wherein the mammal is further administered a therapeutically effective amount of an ABC transporter inhibitor, whereby the neurodegenerative disease is treated in the mammal. In certain embodiments, the neurodegenerative disease comprises at least one selected from the group consisting of spinal cord injury, Alzheimer's disease, Parkinson's disease, Huntington's disease, prion disease, amyotrophic lateral sclerosis, a tauopathy, and chronic traumatic encephalopathy.Type: GrantFiled: February 28, 2019Date of Patent: June 28, 2022Assignee: Thomas Jefferson UniversityInventors: Davide Trotti, Piera Pasinelli, Michael R. Jablonski
-
Patent number: 11279763Abstract: In certain embodiments, the present invention provides methods of suppressing valvulogenesis (VG) in a lymphatic vessel in an inflamed or transplanted tissue or organ in a mammal in need thereof comprising administering an effective amount of an anti-integrin alpha 9 (Itga-9) therapeutic agent to the mammal, and optionally by administering anti-VEGFR-3 agent.Type: GrantFiled: October 26, 2017Date of Patent: March 22, 2022Assignee: The Regents of the University of CaliforniaInventor: Lu Chen
-
Patent number: 11253597Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: GrantFiled: July 3, 2018Date of Patent: February 22, 2022Assignees: Georgia Tech Research Corporation, Children's Healthcare of AtlantaInventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 11203641Abstract: The subject matter of the present invention relates to an in vitro method for the screening of anti-cancer compounds based on the capacity for these compound to interact with netrin-1 receptor and/or to inhibit the dimerization of the intracellular domain of the netrin-1 receptor expressed in tumor cells. The invention also relates to a method for predicting the presence of metastatic or aggressive cancer, or for determining the efficiency of an anti-cancer treatment based on the measuring of the expression level of netrin-1. The invention further comprises kits and compounds as a medicament for the treatment of cancer such as metastatic breast cancer, related to the overexpression of netrin-1 by the tumor cells.Type: GrantFiled: June 21, 2018Date of Patent: December 21, 2021Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS), CENTRE LEON BERARDInventors: Patrick Mehlen, Agnes Bernet, Julien Fitamant
-
Patent number: 11066444Abstract: Provided herein are peptide amphiphiles with binding affinity for the bone promoting growth factor BMP-2, and methods of use thereof. In particular nanofibers and gel scaffolds of BMP-2-binding peptide amphiphiles are provided.Type: GrantFiled: August 6, 2019Date of Patent: July 20, 2021Assignee: Northwestern UniversityInventors: Samuel I. Stupp, Erin L. Hsu, Wellington K. Hsu, Sungsoo Lee
-
Patent number: 11000225Abstract: Various embodiments of the present technology generally relate to a single monolithic IC to perform simultaneous optogenetic neural inhibition and extracellular electrophysiological recording in-vivo. Some embodiments include a low input capacitance (e.g., 9.7 pF) amplifier particularly tailored for the use of high-impedance electrodes to conduct single neuron extracellular recording integrated with programmable high current drivers for optogenetic stimulation or inhibition on the same IC chip. Some embodiments use a noise model to guide the IC design process to obtain parameters for optimal signal-to-noise ratio. The performance of the IC chip was demonstrated on an anesthetized gerbil expressed with inhibitory optogenetic protein (Halorhodopsin). Spontaneous action potentials from the fifth nerve of the brainstem were recorded by the amplifier and were subsequently inhibited by laser illumination.Type: GrantFiled: June 29, 2018Date of Patent: May 11, 2021Assignees: The Regents of the University of Colorado, University of MacauInventors: Tim Lei, Achim Klug, Sio Hang Pun, Changhao Chen, Mang I. Vai, Peng Un Mak, Elizabeth McCullagh
-
Patent number: 10851412Abstract: The invention provides cell potency assays for measuring, determining, identifying, confirming, or validating the therapeutic potential of a cell population. Cell potency assays may be performed with various types of cells, including stem or progenitor cells, such as, for example, hematopoietic stem or progenitor cells. Cell potency assays may also be performed on stem or progenitor cells that have been treated with one or more agents to enhance therapeutic potential. Hematopoietic cells having therapeutic potential are useful in downstream clinical applications for increasing engraftment, reconstitution, homing, and proliferation in vivo.Type: GrantFiled: March 11, 2014Date of Patent: December 1, 2020Assignee: Fate Therapeutics, Inc.Inventors: Daniel Shoemaker, David L. Robbins
-
Patent number: 10758636Abstract: The present invention relates to conjugates including a residualizing linker, methods for their production, and uses thereof.Type: GrantFiled: November 12, 2014Date of Patent: September 1, 2020Assignee: CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATIONInventors: John Fitzmaurice Valliant, Eric Steven Burak, Neil Grant Cockburn, Alla Darwish, Joel Adamson Drewry, John Richard Forbes, Meiduo Hu, Ryan Wayne Simms, Karin Ann Stephenson, Tao Wu
-
Patent number: 10745454Abstract: The embodiments herein disclose a method for synthesizing antagonistic peptide VEGF and bFGF. The method comprises synthesizing the antagonistic peptide for VEGF and bFGF and analyzing the purity of peptides. The quality of antagonistic peptide for VEGF and bFGF is analyzed by HPLC chromatogram and Mass spectrometry analysis. The biochemical activity of the antagonistic peptide for VEGF and bFGF is analyzed by competitive binding assay, cell proliferation assay, Matrigel assay for anti-angiogenic activity analysis, histopathological staining and Western blot analysis. The competitive binding assay of antagonistic peptide for VEGF and bFGF illustrate that peptides binds with cell receptors at a concentration of 2000 ng/ml. The cell proliferation assay illustrates that cell growth is arrested when antagonistic peptide for VEGF and bFGF are at a concentration of 2000 ng/ml.Type: GrantFiled: July 23, 2018Date of Patent: August 18, 2020Inventors: Seyed Mohsen Asghari, Somayeh Ehtesham
-
Patent number: 10081667Abstract: A composition including an elastin-like polypeptide (ELP) coupled to a therapeutic agent is provided. The ELP comprises at least about 5 repeats of the amino acid sequence VPGXG. Further provided is a method of using the composition for therapeutic agent delivery during pregnancy to reduce the amount of the therapeutic agent crossing a placenta in a pregnant subject. The method includes administering to the pregnant subject an effective amount of the composition comprising the ELP coupled to the therapeutic agent.Type: GrantFiled: October 1, 2014Date of Patent: September 25, 2018Assignee: University of Mississippi Medical CenterInventors: Gene L. Bidwell, III, Eric M. George
-
Patent number: 10039831Abstract: Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.Type: GrantFiled: March 19, 2012Date of Patent: August 7, 2018Assignees: Georgia Tech Research Corporation, Children's Healthcare of Atlanta, Inc.Inventors: Niren Murthy, Christopher Hermann, David Scott Wilson, Xinghai Ning, Barbara D. Boyan, Zvi Schwartz, Robert Guldberg, Tamim Diab
-
Patent number: 9119974Abstract: The present invention relates to skin care compositions, including cosmeceuticals, for topical application, and more particularly, a skin cream, comprising exosomes and cell culture medium conditioned by cells grown in two-dimensional culture. Also included are methods of making and using such compositions and kits comprising the skin cream therein.Type: GrantFiled: July 18, 2013Date of Patent: September 1, 2015Inventor: Ahmed H. Al-Qahtani
-
Publication number: 20150132354Abstract: The invention provides a novel composite bone graft system utilizing a porous collagen scaffold having a matrix impregnated with calcium phosphate particles and more than one bioactive agent, one of which is conjugated to the matrix. The graft system exhibits increased mechanical strength and osteogenic properties by providing sites for tissue attachment and propagation. The bioactive agents are delivered to the scaffold via different mechanisms to enable sequential and sustained release of the bioactive agents over time.Type: ApplicationFiled: August 5, 2014Publication date: May 14, 2015Applicant: UNIVERSITY OF NOTRE DAME DU LACInventors: Ryan K. Roeder, Matthew J. Meagher, Robert J. Kane
-
Publication number: 20150126446Abstract: The present invention provides variant VEGF polypeptides which have been altered in their C-terminal heparin binding region to lower their heparin binding affinity. These variants have been found to act as receptor antagonists for VEGF receptors and antagonize angiogenesis. These variants are useful to treat diseases characterized by pathological angiogenesis.Type: ApplicationFiled: April 26, 2013Publication date: May 7, 2015Applicant: The United States of America, as represented by the Secretary, Dept. of Health & Human ServicesInventors: Donald P. Bottaro, Fabiola Cecchi
-
Patent number: 9012399Abstract: The present invention comprises compositions, methods, and devices for delivering angiogenic factors and signaling molecules to a target tissue, and controlling the release of these factors and signaling molecules to spatially and temporally restrict their release and dissemination, for the purpose of promoting angiogenesis in target tissues.Type: GrantFiled: June 1, 2009Date of Patent: April 21, 2015Assignee: President and Fellows of Harvard CollegeInventors: Lan Cao, David J. Mooney
-
Publication number: 20150093375Abstract: The present invention provides methods of using TSPAN12 and Norrin antagonists to inhibit ocular vascular development and to treat related disorders.Type: ApplicationFiled: April 25, 2014Publication date: April 2, 2015Applicant: GENENTECH, INC.Inventors: Harald J. JUNGE, Weilan YE
-
Publication number: 20150086599Abstract: Provided are systems for controlled release of proteins from decomposable thin films constructed by layer-by-layer deposition. Such films generally comprise alternating layers of polymers and proteins, and may further comprise additional layers of polyions. In some embodiments, decomposable thin films and methods of using such films allow proteins to be released over an extended period of time and/or retention of as much as 100% of function of released protein.Type: ApplicationFiled: October 10, 2014Publication date: March 26, 2015Inventors: Paula T. Hammond, Mara L. Macdonald
-
Publication number: 20150080299Abstract: Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7.Type: ApplicationFiled: April 11, 2014Publication date: March 19, 2015Applicant: Stryker CorporationInventor: Niles Ron
-
Patent number: 8968716Abstract: Disclosed herein are an in situ-forming, bioadhesive hydrogel and the medical uses thereof. Being formed by in situ crosslinking through an enzymatic reaction, the hydrogel has an advantage over conventional bioadhesive hydrogels in terms of biocompatibility. In addition, the in situ-forming bioadhesive hydrogel has excellent biocompatibility and mechanical strength and has excellent tissue adhesiveness thanks to modification with/without dopa derivatives. The hydrogel finds a variety of applications in the biomedical field, including bioadhesives or hemostats, implant substances for tissue regeneration and augmentation, carriers for delivering biologically active materials or drugs, etc.Type: GrantFiled: September 2, 2010Date of Patent: March 3, 2015Assignee: Ajou University Industry-Academic Cooperation FoundationInventors: Ki-Dong Park, Yoon-Ki Joung, Kyung-Min Park, Eu-Gene Lih
-
Publication number: 20150056161Abstract: This invention provides a method of treating a disorder of a subject's heart involving loss of cardiomyocytes which comprises administering to the subject a composition comprising an amount of a human stromal derived factor-1 and an amount of a human granulocyte-colony stimulating factor, the composition being administered in an amount effective to cause proliferation of cardiomyocytes within the subject's heart so as to thereby treat the disorder. This invention also provides a method of treating a subject suffering from a disorder of a tissue involving loss and/or apoptosis of cells of the tissue which comprises administering to the subject a composition comprising an amount of an agent which induces phosphorylation and/or activation of protein kinase B, or an agent which induces phosphorylation and/or activation of an extracellular signal-regulated protein kinase, or an agent which induces activation of CXCR4.Type: ApplicationFiled: March 4, 2014Publication date: February 26, 2015Applicant: The Trustees of Columbia University in the City of New YorkInventor: Silviu Itescu
-
Patent number: 8962555Abstract: The present invention relates to a new homodimeric form of recombinant PlGF-1, to a process for its preparation and to compositions containing it.Type: GrantFiled: September 9, 2010Date of Patent: February 24, 2015Assignees: Dompe S.p.A., Geymonat S.p.A.Inventors: Gaetano D'Anniballe, Franck Martin, Giuseppe Salvia
-
Publication number: 20150050332Abstract: In various embodiments, the present invention describes materials and methods for the local reprogramming of cells in a location where the treatment is applied. The invention can be used to replace lost cells or to restore function to tissue damaged due to disease, injury or genetic defect. In various embodiments, the treatment includes a semisolid hydrogel embedded with liposomes. The liposomes can contain an effector molecule or molecules. When phagocytic cells such as monocytes infiltrate the hydrogel, they encounter the liposomes and incorporate the liposomes carrying the effector molecules into the cells. In some embodiments, the effector molecules can be genetic material encoding the expression of specific proteins such as transcription factors, the expression of which can initiate the reprogramming of the cells. In other embodiments, the effector molecules can induce angiogenesis. In other embodiments, the effector molecules are tumor antigens.Type: ApplicationFiled: November 3, 2014Publication date: February 19, 2015Inventor: Shai Yehoshua Schubert
-
Publication number: 20150050331Abstract: The present invention is directed to a method of making a stable composition comprising growth factors, which may include platelet derived growth factors and transforming growth factors. The method comprises providing human umbilical cord blood plasma containing platelets, but substantially free of whole blood cells, and lysing the platelets to extrude growth factors into the plasma. The plasma may be obtained from multiple donors and pooled to form a homologous plasma mixture. In another embodiment, the growth factors are encapsulated in a liposome formed by a lipid bilayer, wherein the resulting composition remains stable and viable for at least 30 months. The present invention is also directed to the composition produced by the methods of the present invention and the process of applying the composition to a skin defect or wound.Type: ApplicationFiled: October 29, 2014Publication date: February 19, 2015Applicant: NOVO SOLUTIONS MD, LLCInventor: ALVIN DAVID NEEDLEMAN
-
Publication number: 20150051147Abstract: The invention is directed to methods for treating Hidradenitis Suppurativa. Specifically, the invention is directed to treating and reducing inflammation associated Hidradenitis Suppurativa by administering to a subject suffering from this condition novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions).Type: ApplicationFiled: August 12, 2014Publication date: February 19, 2015Applicant: STEMNION, INC.Inventors: George L. Sing, Randall G. Rupp, David L Steed
-
Publication number: 20150044166Abstract: Methods, compositions, and medical device systems relating to treating exercise-induced pulmonary hemorrhage (EIPH) and nasopharyngeal cicatrix (NC) in a mammal. For example, one method comprises administering through inhalation a composition comprising a physiologically acceptable carrier and an effective amount of each of one or more stem cell derived factors. Exemplary stem cell derived factors include, but are not limited to, growth factors, chemokines, and cytokines. The mammal may be a horse, dog, camel, or Homo sapiens.Type: ApplicationFiled: August 7, 2014Publication date: February 12, 2015Inventor: Michael Riddle, JR.
-
Publication number: 20150025007Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 1, 2014Publication date: January 22, 2015Inventors: Charlotte A. Emig, Catherine J. Trumpower, George L. Sing
-
Publication number: 20150024051Abstract: A bone implant primer is provided. A biodegradable hydrogel component is provided. A plurality of biomolecule release depots are dispersed within the biodegradable hydrogel component wherein the plurality of biomolecule release depots comprise biomolecules for aiding implant osseointegration or biomolecules for mitigation of foreign body response. Different biomolecules may be released by the microspheres at different times.Type: ApplicationFiled: February 15, 2013Publication date: January 22, 2015Inventors: Michael Gerard Keeney, Fan Yang, Stuart Barry Goodman
-
Publication number: 20150023911Abstract: The present invention relates to an in vitro or ex vivo method of preparing a cell-free composition, said method comprising or consisting of (a) subjecting cells to stress; and (b) collecting factors produced, preferably secreted by said cells when subjected to said stress, thereby obtaining said cell-free composition; wherein said cells are comprised in or form at least one first carrier and said collecting is effected by means of at least one second carrier which second carrier(s) is/are cell-free and concomitantly present with and spatially distinct from said first carrier; and said collecting is effected using a device comprising or consisting of (i) said first carrier(s) which first carrier(s) comprise(s) said cells or is/are suitable to hold said cells; (ii) said second carrier(s) which is cell-free; and (iii) means of subjecting said cells in said first carrier to stress; wherein first carrier(s) and second carrier(s) are positioned such that factors secreted by said cells when subjected to stress areType: ApplicationFiled: January 31, 2013Publication date: January 22, 2015Applicant: Technische Universitaet Muenchen-Klimikum Rechts Der IsarInventors: Arndt Schilling, Ektoras Hadjipanayi, Hans-Guenther Machens
-
Bone regeneration using biodegradable polymeric nanocomposite materials and applications of the same
Patent number: 8936805Abstract: A structure of, and a method of producing, a biocompatible structure for bone and tissue regeneration are disclosed. The method includes dissolving a polyurethane polymer in methanol, adding hydroxyapatite (HAP) nanoparticles to form a uniformly distributed mixture, applying the mixture to a polytetrafluoroethylene (PTFE) surface to form a polymer film, cutting the polymer film into strips, stacking the strips with layers of bone particles disposed therebetween, coating the stacked strips and layers by the mixture and allowing it to dry, adding bone particles to the coating, and plasma treating the structure to form the biocompatible structure. A weight percentage of the HAP nanoparticles to the polymer is about 5-50% such that a resorption rate of the biocompatible structure substantially matches a rate of tissue generation in the biocompatible structure.Type: GrantFiled: July 22, 2013Date of Patent: January 20, 2015Assignee: Board of Trustees of the University of ArkansasInventor: Alexandru S. Biris -
Patent number: 8936804Abstract: This invention provides a method of promoting bone healing by locally administering a vanadium-based insulin mimetic agent to a patient in need thereof. The invention also provides a new use of insulin-mimetic vanadium compounds for manufacture of medicaments for accelerating bone-healing processes. In addition, the invention also encompasses a bone injury treatment kit suitable for localized administration of insulin-mimetic vanadium compounds or compositions thereof to a patient in need of such treatment.Type: GrantFiled: January 14, 2011Date of Patent: January 20, 2015Assignee: Rutgers, The State University of New JerseyInventors: Sheldon Suton Lin, David Naisby Paglia, James Patrick O'Connor, Eric Breitbart, Joseph Benevenia
-
Publication number: 20150018750Abstract: As the percentage of senior citizens increases at the present time, the purpose of the present invention is to provide a cosmetic which can maintain the skin in a healthy state by preventing damage to the skin that accompanies aging, more specifically, discoloration and wrinkling, is very safe, does not pose ethical problems, and can be supplied in a sufficient amount. The present invention provides a cosmetic that comprises as the main component a powder of the supernatant produced by culturing the bone marrow or dental pulp stem cells of a nonhuman mammal. Moreover, provided is a method for ion introduction for protein by which the cosmetic is introduced by ion introduction.Type: ApplicationFiled: August 8, 2014Publication date: January 15, 2015Applicant: JAPANIC CORPORATIONInventors: Minoru Ueda, Yasuhiro Yamashita
-
Patent number: 8927232Abstract: The present application describes an isolated nucleic acid molecule encoding a polypeptide capable of synchronously binding VEGF polypeptide and TNF polypeptide comprising: (a) a nucleotide sequence encoding a TNFR2 component and VEGFR1 component operatively linked to (b) a nucleotide sequence encoding a multimerizing component, wherein the TNFR2 component consists essentially of a nucleotide sequence encoding the amino acid sequences of cystein rich domain 1, cystein rich domain 2, cystein rich domain 3, and cystein rich domain 4 of the extracellular domain of TNFR2, and wherein the VEGFR1 component consists essentially of a nucleotide sequence encoding the amino acid sequences of Ig-like domain 2 of the extracellular domain of VEGFR1.Type: GrantFiled: December 11, 2009Date of Patent: January 6, 2015Assignee: Korea Advanced Institute of Science and Technology (KAIST)Inventors: Keehoon Jung, Young Jun Koh, Gyun Min Lee, Sun Chang Kim, Gou Young Koh
-
Publication number: 20150005234Abstract: Provided herein are soft tissue implants, methods of making, use, and administration thereof. The soft tissue implants can be prepared by harvesting cells or tissue from a donor and selectively lysing the cells or tissue to obtain the intracellular content. Also provided herein are delivery devices for delivering the soft tissue implants described herein and kits that include the soft tissue implants described herein.Type: ApplicationFiled: July 1, 2014Publication date: January 1, 2015Inventor: Amit Prakash Govil
-
Publication number: 20150005235Abstract: Polypeptides comprising variant vascular endothelial growth factor sequences are provided. The polypeptides are useful in cancer imaging, cancer diagnosis, monitoring and treatment as well as treatment of diseases characterized by excessive neovascularization.Type: ApplicationFiled: September 3, 2014Publication date: January 1, 2015Inventors: Jennifer R. Cochran, Adam Silverman, Douglas Jones, Niv Papo
-
Patent number: 8921316Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: GrantFiled: June 4, 2013Date of Patent: December 30, 2014Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel Dix, Kelly Frye, Susan Kautz
-
Publication number: 20140377276Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.Type: ApplicationFiled: January 24, 2014Publication date: December 25, 2014Applicant: Genentech, Inc.Inventors: Napoleone Ferrara, Kyung Jin Kim